Intravenous monoclonal antibody (BT 5/9) for the treatment of acute graft-versus-host disease

A. Bacigalupo, G. Corte, D. Ramarli, M. T. van Lint, F. Frassoni, A. Marmont

Research output: Contribution to journalArticlepeer-review

Abstract

Treatment with this Mab is well tolerated with acceptable immediate adverse reactions. Candida infections are a problem, possibly due to immunosuppression. A significant proportion of patients showed improvement of GvHD, and 63% survive 1 year later. We have not as yet observed the occurrence of malignant lymphomas.

Original languageEnglish
Pages (from-to)185-186
Number of pages2
JournalActa Haematologica
Volume73
Issue number3
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Intravenous monoclonal antibody (BT 5/9) for the treatment of acute graft-versus-host disease'. Together they form a unique fingerprint.

Cite this